Anavex Life Sciences Corp. (AVXL)
2.61
-0.01
(-0.38%)
USD |
NASDAQ |
Sep 14, 16:00
2.61
0.00 (0.00%)
After-Hours: 18:13
Anavex Life Sciences Enterprise Value : 124.54M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 124.54M |
| September 10, 2026 | 128.25M |
| September 09, 2026 | 136.59M |
| September 08, 2026 | 145.86M |
| September 04, 2026 | 146.79M |
| September 03, 2026 | 145.86M |
| September 02, 2026 | 149.57M |
| September 01, 2026 | 147.71M |
| August 31, 2026 | 141.22M |
| August 28, 2026 | 158.84M |
| August 27, 2026 | 171.82M |
| August 26, 2026 | 182.01M |
| August 25, 2026 | 211.67M |
| August 24, 2026 | 169.96M |
| August 21, 2026 | 182.01M |
| August 20, 2026 | 171.82M |
| August 19, 2026 | 195.92M |
| August 18, 2026 | 178.30M |
| August 17, 2026 | 179.23M |
| August 14, 2026 | 180.16M |
| August 13, 2026 | 184.79M |
| August 12, 2026 | 197.77M |
| August 11, 2026 | 207.04M |
| August 10, 2026 | 195.92M |
| August 07, 2026 | 191.28M |
| Date | Value |
|---|---|
| August 06, 2026 | 185.72M |
| August 05, 2026 | 178.30M |
| August 04, 2026 | 173.67M |
| August 03, 2026 | 155.13M |
| July 31, 2026 | 136.59M |
| July 30, 2026 | 131.96M |
| July 29, 2026 | 112.49M |
| July 28, 2026 | 119.90M |
| July 27, 2026 | 113.42M |
| July 24, 2026 | 104.15M |
| July 23, 2026 | 111.56M |
| July 22, 2026 | 118.05M |
| July 21, 2026 | 118.51M |
| July 20, 2026 | 106.00M |
| July 17, 2026 | 103.22M |
| July 16, 2026 | 98.58M |
| July 15, 2026 | 113.42M |
| July 14, 2026 | 106.93M |
| July 13, 2026 | 99.51M |
| July 10, 2026 | 113.42M |
| July 09, 2026 | 131.96M |
| July 08, 2026 | 131.96M |
| July 07, 2026 | 132.88M |
| July 06, 2026 | 128.25M |
| July 02, 2026 | 137.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.47B |
| Oncolytics Biotech, Inc. | 89.25M |
| Sangamo Therapeutics, Inc. | 53.27M |
| Sarepta Therapeutics, Inc. | 2.417B |
| Anixa Biosciences, Inc. | 80.49M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 7.824M |
| Total Expenses (Quarterly) | -7.824M |
| EPS Diluted (Quarterly) | 0.0842 |
| Earnings Yield | -5.81% |
| Normalized Earnings Yield | -5.808 |